Wednesday, December 6, 2023
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Professor of Medicine
Knight Cancer Institute
Oregon Health & Science University
Portland, Oregon, United States
Geoffrey Beene Junior Faculty Chair
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Head of the Department of General Medical Oncology
University Hospitals Leuven
Leuven, Belgium
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Peer Reviewer
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This educational activity is intended for a global audience of hematology/oncology specialists and gastroenterologists.
The goal of this activity is to provide clinicians who treat patients with gastrointestinal stromal tumor (GIST) with updates regarding current and novel therapies and to provide practical considerations related to the application of new data to improve patient outcomes and preserve quality of life.
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Professor of Medicine
Knight Cancer Institute
Oregon Health & Science University
Portland, Oregon, United States
Geoffrey Beene Junior Faculty Chair
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Head of the Department of General Medical Oncology
University Hospitals Leuven
Leuven, Belgium
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Peer Reviewer
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 8/25/2020
Valid for credit through: 8/25/2021, 11:59 PM EST
processing....
AE = adverse event
ASCO = American Society of Clinical Oncology
ATP = adenosine triphosphate
CBR = clinical benefit rate
CI = confidence interval
CMR = complete metabolic response
CT = computed tomography
ECOG = Eastern Cooperative Oncology Group
EGD = esophagogastroduodenoscopy
EMA = European Medicines Agency
EORTC = European Organisation for Research and Treatment of Cancer
ESMO = European Society of Medical Oncology
FDA = US Food and Drug Administration
FGFR = fibroblast growth factor receptor
GIST = gastrointestinal stromal tumor
HR = hazard ratio
IHC = immunohistochemistry
IM = imatinib
IV = intravenous
JM = juxtamembrane
mDOR = median duration of response
mTTP = median time to progression
Mut = mutant
NCCN = National Comprehensive Cancer Network
NIL = nilotinib
NR = not reported
NTRK = neurotrophic tyrosine receptor kinase
ORR = objective response rate
OS = overall survival
PD = progressive disease
PDGFRA = platelet-derived growth factor receptor-alpha
PET = positron emission tomography
PFS = progression-free survival
PMR = partial metabolic response
pNET = pancreatic neuroendocrine tumor
PPE = palmar-plantar erythrodysesthesia
PR = partial response
PS = performance status
R = randomization
RCR = resectability conversion rate
RCT = randomized controlled trial
RECIST = Response Evaluation Criteria in Solid Tumors
RP2D = recommended phase 2 dose
RR = response rate
SD = stable disease
SDHB = succinate dehydrogenase B
SMD = stable metabolic disease
SOC = standard of care
SOR = sorafenib
SU = sunitinib
TK = tyrosine kinase
TKI = tyrosine kinase inhibitor
TTP = time to progression
VEGFR = vascular endothelial growth factor receptor
WT = wild type
| « Return to: Changing Paradigms in the Management of Advanced GIST Implications and Application of New Strategies |
